TargetMol

AF 399

Product Code:
 
TAR-T23646
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T23646-1mg1mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23646-1mL1 mL * 10 mM (in DMSO)£326.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23646-5mg5mg£340.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23646-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23646-25mg25mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23646-50mg50mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23646-100mg100mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23646-500mg500mg£2,456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AF 399 is a CCR4 antagonist. It reverses the tumor-promoting environment.
CAS:
91533-02-7
Formula:
C12H17N3O3S
Molecular Weight:
283.35
Purity:
0.9921
SMILES:
NS(=O)(=O)c1ccc(NC(=O)CN2CCCC2)cc1

References

1. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Lip GYH, Chen SA. Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation - A Nationwide Cohort Study. Circulation. 2018 Feb 28. pii: CIRCULATIONAHA.117.031658. doi: 10.1161/CIRCULATIONAHA.117.031658. [Epub ahead of print] PubMed PMID: 29490992. 2. Conti S, Reiffel JA, Gersh BJ, Kowey PR, Wachter R, Halperin JL, Kaplon RE, Pouliot E, Verma A. Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. J Atr Fibrillation. 2017 Feb 28;9(5):1551. doi: 10.4022/jafib.1551. eCollection 2017 Feb-Mar. PubMed PMID: 29250279; PubMed Central PMCID: PMC5673395. 3. Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, Knecht S, Tavernier R, Vandekerckhove Y, De Potter T. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018 Apr 21;39(16):1429-1437. doi: 10.1093/eurheartj/ehx666. PubMed PMID: 29211857. 4. Chou PS, Ho BL, Chan YH, Wu MH, Hu HH, Chao AC. Delayed diagnosis of atrial fibrillation after first-ever stroke increases recurrent stroke risk: A 5-year nationwide follow-up study. Intern Med J. 2017 Nov 29. doi: 10.1111/imj.13686. [Epub ahead of print] PubMed PMID: 29193638.